NCT01221857View on ClinicalTrials.gov

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

May 31, 2013

Conditions
Acute Lymphoblastic Leukemia (ALL)Acute Myelogenous Leukemia (AML)Myelodysplastic Syndrome (MDS)Non-Hodgkin's LymphomaHodgkin's Disease
Interventions
DRUG

NiCord®

NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.

Trial Locations (2)

27705

Duke University Medical Center, Durham

60153

Loyola University, Cardinal Bernardin Cancer Center, Maywood

Sponsors

Lead Sponsor

Gamida Cell ltd
All Listed Sponsors
lead

Gamida Cell ltd

INDUSTRY